{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T22:43:46Z","timestamp":1761864226039,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T00:00:00Z","timestamp":1609632000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"name":"This was an academic study. A research grant and drug supply during panitumumab-based maintenance treatment was provided by Amgen"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2021,7]]},"DOI":"10.1007\/s00520-020-05972-2","type":"journal-article","created":{"date-parts":[[2021,1,3]],"date-time":"2021-01-03T18:03:05Z","timestamp":1609696985000},"page":"3971-3980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study"],"prefix":"10.1007","volume":"29","author":[{"given":"Alessandra","family":"Raimondi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Corallo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara","family":"Lonardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlotta","family":"Antoniotti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenza","family":"Rimassa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessio","family":"Amatu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tampellini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrizia","family":"Racca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Murialdo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Clavarezza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Zaniboni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Toscano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gianluca","family":"Tomasello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fausto","family":"Petrelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorenzo","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saverio","family":"Cinieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raffaella","family":"Longarini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica","family":"Niger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Antista","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margherita","family":"Ambrosini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Pagani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Prisciandaro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giovanni","family":"Randon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"de Braud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Di Bartolomeo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8530-8420","authenticated-orcid":false,"given":"Filippo","family":"Pietrantonio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Federica","family":"Morano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,1,3]]},"reference":[{"issue":"8","key":"5972_CR1","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1093\/annonc\/mdw235","volume":"27","author":"E Van Cutsem","year":"2016","unstructured":"Van Cutsem E, Cervantes A, Adam R et al (2016) ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 27(8):1386\u20131422","journal-title":"Ann Oncol"},{"issue":"17","key":"5972_CR2","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","volume":"371","author":"F Loupakis","year":"2014","unstructured":"Loupakis F, Cremolini C, Masi G, Lonardi S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi R, Zaniboni A, Tonini G, Buonadonna A, Amoroso D, Chiara S, Carlomagno C, Boni C, Allegrini G, Boni L, Falcone A (2014) Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 371(17):1609\u20131618","journal-title":"N Engl J Med"},{"issue":"4","key":"5972_CR3","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(19)30862-9","volume":"21","author":"C Cremolini","year":"2020","unstructured":"Cremolini C, Antoniotti C, Rossini D, Lonardi S, Loupakis F, Pietrantonio F, Bordonaro R, Latiano TP, Tamburini E, Santini D, Passardi A, Marmorino F, Grande R, Aprile G, Zaniboni A, Murgioni S, Granetto C, Buonadonna A, Moretto R, Corallo S, Cordio S, Antonuzzo L, Tomasello G, Masi G, Ronzoni M, di Donato S, Carlomagno C, Clavarezza M, Ritorto G, Mambrini A, Roselli M, Cupini S, Mammoliti S, Fenocchio E, Corgna E, Zagonel V, Fontanini G, Ugolini C, Boni L, Falcone A, GONO Foundation Investigators (2020) Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 21(4):497\u2013507","journal-title":"Lancet Oncol"},{"key":"5972_CR4","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.ejca.2018.12.019","volume":"109","author":"DP Modest","year":"2019","unstructured":"Modest DP, Pant S, Sartore-Bianchi A (2019) Treatment sequencing in metastatic colorectal cancer. Eur J Cancer 109:70\u201383","journal-title":"Eur J Cancer"},{"issue":"23","key":"5972_CR5","doi-asserted-by":"publisher","first-page":"2392","DOI":"10.1001\/jama.2017.7105","volume":"317","author":"AP Venook","year":"2017","unstructured":"Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, el-Khoueiry AB, Watson P, Benson AB III, Mulkerin DL, Mayer RJ, Blanke C (2017) Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer: a randomized clinical trial. JAMA. 317(23):2392\u20132401","journal-title":"JAMA."},{"key":"5972_CR6","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1016\/S1470-2045(16)30269-8","volume":"17","author":"S Stintzing","year":"2016","unstructured":"Stintzing S, Modest DP, Rossius L, Lerch MM, von Weikersthal L, Decker T, Kiani A, Vehling-Kaiser U, al-Batran SE, Heintges T, Lerchenm\u00fcller C, Kahl C, Seipelt G, Kullmann F, Stauch M, Scheithauer W, Held S, Giessen-Jung C, Moehler M, Jagenburg A, Kirchner T, Jung A, Heinemann V, FIRE-3 investigators (2016) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 17:1426\u20131434","journal-title":"Lancet Oncol"},{"key":"5972_CR7","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1056\/NEJMoa1305275","volume":"369","author":"JY Douillard","year":"2013","unstructured":"Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Koc\u00e1kova I, Ruff P, B\u0142asi\u0144ska-Morawiec M, \u0160makal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369:1023\u20131034","journal-title":"N Engl J Med"},{"key":"5972_CR8","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.ejca.2016.10.007","volume":"70","author":"JW Holch","year":"2017","unstructured":"Holch JW, Ricard I, Stintzing S, Modest DP, Heinemann V (2017) The relevance of primary tumour location in patients with metastatic colorectal cancer: a meta-analysis of first-line clinical trials. Eur J Cancer 70:87\u201398","journal-title":"Eur J Cancer"},{"issue":"14","key":"5972_CR9","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1200\/JCO.18.01798","volume":"37","author":"F Innocenti","year":"2019","unstructured":"Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O (2019) Mutational analysis of patients with colorectal cancer in CALGB\/SWOG 80405 identifies new roles of microsatellite instability and tumor mutational burden for patient outcome. J Clin Oncol 37(14):1217\u20131227","journal-title":"J Clin Oncol"},{"key":"5972_CR10","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1093\/annonc\/mdx546","volume":"28","author":"C Cremolini","year":"2017","unstructured":"Cremolini C, Morano F, Moretto R, Berenato R, Tamborini E, Perrone F, Rossini D, Gloghini A, Busico A, Zucchelli G, Baratelli C, Tamburini E, Tampellini M, Sensi E, Fuc\u00e0 G, Volpi C, Milione M, di Maio M, Fontanini G, de Braud F, Falcone A, Pietrantonio F (2017) Negative hyper-selection of metastatic colorectal cancer patients for anti-EGFR monoclonal antibodies: the PRESSING case-control study. Ann Oncol 28:3009\u20133014","journal-title":"Ann Oncol"},{"issue":"33","key":"5972_CR11","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1200\/JCO.19.01254","volume":"37","author":"F Morano","year":"2019","unstructured":"Morano F, Corallo S, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Murialdo R, Zaniboni A, Sartore-Bianchi A, Tomasello G, Racca P, Clavarezza M, Adamo V, Perrone F, Gloghini A, Tamborini E, Busico A, Martinetti A, Palermo F, Loupakis F, Milione M, Fuc\u00e0 G, di Bartolomeo M, de Braud F, Pietrantonio F (2019) Negative hyperselection of patients with RAS and BRAF wild-type metastatic colorectal cancer who received panitumumab-based maintenance therapy. J Clin Oncol 37(33):3099\u20133110","journal-title":"J Clin Oncol"},{"key":"5972_CR12","unstructured":"https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/information-cetuximab-marketed-erbitux. Accessed online 20 Nov 2020"},{"issue":"20","key":"5972_CR13","first-page":"30046","volume":"S1533-0028","author":"D Rossini","year":"2020","unstructured":"Rossini D, Germani MM, Pagani F et al (2020) Retreatment with anti-EGFR antibodies in metastatic colorectal cancer patients: a multi-institutional analysis. Clin Colorectal Cancer S1533-0028(20):30046\u201330043","journal-title":"Clin Colorectal Cancer"},{"issue":"3","key":"5972_CR14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","volume":"5","author":"C Cremolini","year":"2019","unstructured":"Cremolini C, Rossini D, Dell'Aquila E et al (2019) Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial. JAMA Oncol 5(3):343\u2013350.15","journal-title":"JAMA Oncol"},{"key":"5972_CR15","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor- associated dermatologic toxicities. Support Care Cancer 19:1079\u20131095","journal-title":"Support Care Cancer"},{"key":"5972_CR16","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero A, Dusza S et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25:5390\u20135396","journal-title":"J Clin Oncol"},{"key":"5972_CR17","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1002\/cncr.23621","volume":"113","author":"A Jatoi","year":"2008","unstructured":"Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL (2008) Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 113:847\u2013853","journal-title":"Cancer"},{"key":"5972_CR18","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1007\/s00520-010-0988-5","volume":"19","author":"A Jatoi","year":"2011","unstructured":"Jatoi A, Dakhil SR, Sloan JA, Kugler JW, Rowland KM Jr, Schaefer PL, Novotny PJ, Wender DB, Gross HM, Loprinzi CL, North Central Cancer Treatment Group (2011) Prophylactic tetracycline does not diminish the severity of epidermal growth factor receptor (EGFR) inhibitor-induced rash: results from the North Central Cancer Treatment Group (Supplementary N03CB). Support Care Cancer 19:1601\u20131607","journal-title":"Support Care Cancer"},{"issue":"8","key":"5972_CR19","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N, Xu F, Yassine M (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351\u20131357","journal-title":"J Clin Oncol"},{"issue":"9","key":"5972_CR20","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1001\/jamaoncol.2019.1467","volume":"5","author":"F Pietrantonio","year":"2019","unstructured":"Pietrantonio F, Morano F, Corallo S, Miceli R, Lonardi S, Raimondi A, Cremolini C, Rimassa L, Bergamo F, Sartore-Bianchi A, Tampellini M, Racca P, Clavarezza M, Berenato R, Caporale M, Antista M, Niger M, Smiroldo V, Murialdo R, Zaniboni A, Adamo V, Tomasello G, Giordano M, Petrelli F, Longarini R, Cinieri S, Falcone A, Zagonel V, di Bartolomeo M, de Braud F (2019) Maintenance therapy with panitumumab alone vs panitumumab plus fluorouracil-leucovorin in patients with RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial. JAMA Oncol 5(9):1268\u20131275","journal-title":"JAMA Oncol"},{"key":"5972_CR21","first-page":"34","volume":"21","author":"LI Wagner","year":"2007","unstructured":"Wagner LI, Lacouture ME (2007) Dermatologic toxicities associated with EGFR inhibitors: the clinical psychologist\u2019s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 21:34\u201336","journal-title":"Oncology (Williston Park)"},{"key":"5972_CR22","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1038\/nrc1970","volume":"6","author":"M Lacouture","year":"2006","unstructured":"Lacouture M (2006) Mechanisms of cutaneous toxicities to EGFR inhibitors. Nat Rev Cancer 6:803\u2013812","journal-title":"Nat Rev Cancer"},{"key":"5972_CR23","doi-asserted-by":"publisher","first-page":"199ra111","DOI":"10.1126\/scitranslmed.3005886","volume":"5","author":"BM Lichtenberger","year":"2013","unstructured":"Lichtenberger BM, Gerber PA, Holcmann M et al (2013) Epidermal EGFR controls cutaneous host defense and prevents inflammation. Sci Transl Med 5:199ra111","journal-title":"Sci Transl Med"},{"issue":"suppl 2","key":"5972_CR24","doi-asserted-by":"publisher","first-page":"S60","DOI":"10.3816\/CCC.2007.s.004","volume":"6","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E (2007) Optimizing administration of epidermal growth factor receptor-targeted agents in the treatment of colorectal cancer. Clin Colorectal Cancer 6(suppl 2):S60\u2013S65","journal-title":"Clin Colorectal Cancer"},{"key":"5972_CR25","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/j.1610-0387.2005.05058.x","volume":"3","author":"S Segaert","year":"2005","unstructured":"Segaert S, Tabernero J, Chosidow O, Dirschka T, Elsner J, Mancini L, Maughan T, Morere JF, Santoro A, Sobrero A, van Cutsem E, Layton A (2005) The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies. J Dtsch Dermatol Ges 3:599\u2013606","journal-title":"J Dtsch Dermatol Ges"},{"key":"5972_CR26","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1159\/000112795","volume":"72","author":"SL Boone","year":"2007","unstructured":"Boone SL, Rademaker A, Liu D, Pfeiffer C, Mauro DJ, Lacouture ME (2007) Impact and management of skin toxicity associated with anti-epidermal growth factor receptor therapy: survey results. Oncology 72:152\u2013159","journal-title":"Oncology"},{"key":"5972_CR27","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1111\/j.1365-2133.2005.07010.x","volume":"154","author":"KY Suh","year":"2006","unstructured":"Suh KY, Kindler HL, Medenica M, Lacouture M (2006) Doxycycline for the treatment of paronychia induced by the epidermal growth factor receptor inhibitor cetuximab. Br J Dermatol 154:191\u2013192","journal-title":"Br J Dermatol"},{"key":"5972_CR28","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1634\/theoncologist.2011-0365","volume":"17","author":"JB Bachet","year":"2012","unstructured":"Bachet JB, Peuvrel L, Bachmeyer C, Reguiai Z, Gourraud PA, Bouch\u00e9 O, Ychou M, Bensadoun RJ, Dreno B, Andr\u00e9 T (2012) Folliculitis induced by EGFR inhibitors, preventive and curative efficacy of tetracyclines in the management and incidence rates according to the type of EGFR inhibitor administered: a systematic literature review. Oncologist 17:555\u2013568","journal-title":"Oncologist"},{"key":"5972_CR29","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00520-015-2846-y","volume":"24","author":"B Dascalu","year":"2016","unstructured":"Dascalu B, Kennecke HF, Lim HJ, Renouf DJ, Ruan JY, Chang JT, Cheung WY (2016) Prophylactic versus reactive treatment of acneiform skin rashes from epidermal growth factor receptor inhibitors in metastatic colorectal cancer. Support Care Cancer 24:799\u2013805","journal-title":"Support Care Cancer"},{"key":"5972_CR30","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1007\/s00432-013-1483-4","volume":"139","author":"TC Wehler","year":"2013","unstructured":"Wehler TC, Graf C, Mohler M et al (2013) Cetuximab-induced skin exanthema: prophylactic and reactive skin therapy are equally effective. J Cancer Res Clin Oncol 139:1667\u20131672","journal-title":"J Cancer Res Clin Oncol"},{"key":"5972_CR31","first-page":"6175","volume":"35","author":"M Yamada","year":"2015","unstructured":"Yamada M, Iihara H, Fujii H, Ishihara M, Matsuhashi N, Takahashi T, Yoshida K, Itoh Y (2015) Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer patients. Anticancer Res 35:6175\u20136181","journal-title":"Anticancer Res"},{"key":"5972_CR32","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","volume":"11","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I, Uebayashi M, Okuda H, Kusumi T, Miyagishima T, Sogabe S, Tateyama M, Hatanaka K, Tsuji Y, Nakamura M, Konno J, Yamamoto F, Onodera M, Iwai K, Sakata Y, Abe R, Oba K, Sakamoto N (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 11:617\u2013627","journal-title":"Future Oncol"},{"issue":"6","key":"5972_CR33","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1111\/bjd.14756","volume":"175","author":"F Petrelli","year":"2016","unstructured":"Petrelli F, Borgonovo K, Cabiddu M, Coinu A, Ghilardi M, Lonati V, Barni S (2016) Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analyis. Br J Dermatol 175(6):1166\u20131174","journal-title":"Br J Dermatol"},{"key":"5972_CR34","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O\u2019Callaghan CJ, Karapetis CS et al (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040\u20132048","journal-title":"N Engl J Med"},{"key":"5972_CR35","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","volume":"8","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 8:173\u2013181","journal-title":"Target Oncol"},{"key":"5972_CR36","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.ejca.2020.04.048","volume":"135","author":"A Raimondi","year":"2020","unstructured":"Raimondi A, Di Maio M, Morano F et al (2020) Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with panitumumab-based first-line treatment strategy: a pre-specified secondary analysis of the Valentino study. Eur J Cancer 135:230\u2013239","journal-title":"Eur J Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05972-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-020-05972-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-020-05972-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,28]],"date-time":"2021-05-28T06:20:34Z","timestamp":1622182834000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-020-05972-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,3]]},"references-count":36,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,7]]}},"alternative-id":["5972"],"URL":"https:\/\/doi.org\/10.1007\/s00520-020-05972-2","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"type":"print","value":"0941-4355"},{"type":"electronic","value":"1433-7339"}],"subject":[],"published":{"date-parts":[[2021,1,3]]},"assertion":[{"value":"8 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FP has received honoraria for speaker activities and participation in advisory boards from Sanofi, Amgen, Bayer, Merck-Serono, Lilly, Roche, Servier, and research grants from BMS.SL has received honoraria for speaker activities and participation in advisory boards from Amgen, Bayer, Merck-Serono, Roche, Servier, and Bristol Myers Squibb.LR has received honoraria for speaker activities and participation in advisory boards from AstraZeneca, AbbVie, Amgen, ArQule, Basilea, Bayer, Celgene, Eisai, Exelixis, Gilead, Hengrui Therapeutics, Incyte, Ipsen, Lilly, Merck Sharp & Dohme, Nerviano Medical Sciences, Roche, Sanofi, and research grants to her Institution from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Lilly, Exelixis, FibroGen, Incyte, Ipsen, Merck Sharp & Dohme, and Roche.PR has received honoraria for speaker activities and participation in advisory boards from Servier, Amgen, Roche, and Merck.AZ has received honoraria for speaker bureau from Sanofi, Amgen, Bayer, Merck-Serono, Lilly, Servier, and Bayer.MDB has received honoraria for speaker activities and participation in advisory boards from Amgen, Roche, Lilly, Servier, Incyte, and Celgene.FM has received honoraria for speaker activities from Servier.FDB has received honoraria for speaker activities and participation in advisory boards from Amgen, Roche, and Novartis. All other authors declared no disclosures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was conducted in accordance with the Declaration of Helsinki and the Good Clinical Practice. Institutional review board and Ethics committee approval was obtained from all participating centers.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent before any study-related procedures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Yes","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"On request","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}